Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01706965 · ClinicalTrials.gov registry record · Phase 1
Kuvan in People With Schizophrenia and Schizoaffective Disorder
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01706965 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 27 participants.
The verdict
NCT01706965, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Rater blinded trial of six weeks of Kuvan vs. multivitamin in 60 outpatients with schizophrenia or schizoaffective disorder. The aims are to evaluate an anticipated clinical response to Kuvan treatment including negative symptom and cognitive deficits, evaluate safety of Kuvan treatment for schizophrenic patients and evaluate the relationship of changes in plasma Kuvan levels and efficacy outcomes.
Interventions
- DRUG Multivitamin
- DRUG Kuvan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01706965
The ClinicalTrials.gov registry entry for NCT01706965 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Multivitamin is the first listed.
NCT01706965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01706965 about?
NCT01706965 is a clinical study titled "Kuvan in People With Schizophrenia and Schizoaffective Disorder". Rater blinded trial of six weeks of Kuvan vs. multivitamin in 60 outpatients with schizophrenia or schizoaffective disorder. The aims are to evaluate an anticipated clinical response to Kuvan treatment including negative symptom and cognitive deficits, evaluate safety of Kuvan treatment for schizoph...
What is the current status of trial NCT01706965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2012-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01706965?
The interventions under investigation include: Multivitamin (DRUG), Kuvan (DRUG).
Who is sponsoring clinical trial NCT01706965?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.